Thomas Stankovich, Chief Financial Officer at ReShape Lifesciences Inc. (RSLS), sold 418 shares at $4.25 ($4K) on 2023-02-28, disclosed to the SEC on 2023-03-07.
Open-market sale of $4k RSLS by Chief Financial Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.49 | 48 | $360 | 9.7% |
| 2 | $7.49 | 110 | $824 | 22.2% |
| 3 | $13.29 | 157 | $2K | 56.3% |
| 4 | $4.25 | 103 | $438 | 11.8% |
| Total | $8.87 avg | 418 | $4K | 100% |
| Filing → |
| RSLS | SELL | 2023-07-19 | $156 | — | Filing → |
| RSLS | BUY | 2023-07-06 | $27K | — | Filing → |
| RSLS | SELL | 2023-07-06 | $746 | — | Filing → |